These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33167720)

  • 21. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
    Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.
    Chang YI; Damnernsawad A; Allen LK; Yang D; Ranheim EA; Young KH; Zhang J; Kong G; Wang J; Liu Y; Fu HY; Yang CS; Guo J; Song H; Zhang J
    Br J Haematol; 2014 Aug; 166(3):461-5. PubMed ID: 24697267
    [No Abstract]   [Full Text] [Related]  

  • 23. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
    Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
    Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation.
    Gao F; Gao Y; Luo Y; Yu J; Fu H; Lai X; Liu L; Ye B; Lan J; Song X; Lu Y; Chen L; Chen Y; Yu K; Huang H; Shi J; Zhao Y
    Am J Hematol; 2022 Feb; 97(2):E44-E47. PubMed ID: 34778993
    [No Abstract]   [Full Text] [Related]  

  • 25. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation.
    Waterhouse M; Bertz H; Finke J
    Ann Hematol; 2014 Feb; 93(2):293-8. PubMed ID: 23907410
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
    Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
    [No Abstract]   [Full Text] [Related]  

  • 28. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
    Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia].
    Li TT; Li J; Geng YH; Zhang F; Liu L; Yang YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):76-81. PubMed ID: 32027256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
    Amit O; On YB; Perez G; Shargian-Alon L; Yeshurun M; Ram R
    Ann Hematol; 2021 Mar; 100(3):817-824. PubMed ID: 33442793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
    Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
    Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed phenotype acute leukemia in a child associated with a NUP98-NSD1 fusion and NRAS p.Gly61Arg mutation.
    Ganapathi SS; Raikar SS; Yatsenko SA; Djokic M; Bukowinski A
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1372. PubMed ID: 33784031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
    Byrne M; Danielson N; Sengsayadeth S; Rasche A; Culos K; Gatwood K; Wyatt H; Chinratanalab W; Dholaria B; Ferrell PB; Fogo K; Goodman S; Jagasia M; Jayani R; Kassim A; Mohan SR; Savani BN; Strickland SA; Engelhardt BG; Savona M
    Am J Hematol; 2020 Sep; 95(9):1006-1014. PubMed ID: 32390196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
    J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.
    Damm F; Markus B; Thol F; Morgan M; Göhring G; Schlegelberger B; Krauter J; Heuser M; Bernard OA; Ganser A
    Genes Chromosomes Cancer; 2014 Oct; 53(10):824-32. PubMed ID: 24898826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
    Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Raedler J; Heyde S; Kolokythas M; Eichinger A; Binder V; Schmid I; Klein C; Feuchtinger T; Albert MH
    Br J Haematol; 2020 Jun; 189(6):e251-e254. PubMed ID: 32342493
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.